VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02)

AIM: VITAL, a phase II single‐arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). METHODS: Adult, treatment‐naïve SCCAC patients (Stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Feliu, Jaime, Garcia‐Carbonero, Rocio, Capdevila, Jaume, Guasch, Inmaculada, Alonso‐Orduna, Vicente, Lopez, Carlos, Garcia‐Alfonso, Pilar, Castanon, Carmen, Sevilla, Isabel, Cerezo, Laura, Conill, Carles, Quintana‐Angel, Begona, Sanchez, Maria E., Ghanem, Ismael, Martin‐Richard, Marta, Lopez‐Gomez, Miriam, Leon, Ana, Caro, Monica, Fernandez, Teresa, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997048/
https://www.ncbi.nlm.nih.gov/pubmed/31851776
http://dx.doi.org/10.1002/cam4.2722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997048/
https://www.ncbi.nlm.nih.gov/pubmed/31851776
http://dx.doi.org/10.1002/cam4.2722

Ejemplares similares